CN109589404A - One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof - Google Patents
One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof Download PDFInfo
- Publication number
- CN109589404A CN109589404A CN201811423700.6A CN201811423700A CN109589404A CN 109589404 A CN109589404 A CN 109589404A CN 201811423700 A CN201811423700 A CN 201811423700A CN 109589404 A CN109589404 A CN 109589404A
- Authority
- CN
- China
- Prior art keywords
- reproductive system
- female reproductive
- product
- ageing
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses one kind for anti-ageing reparation product of female reproductive system and preparation method thereof, and main component includes coumestrol, vitamin E, curcuma zedoary, Sodium Hyaluronate and collagen.The present invention can improve intracorporal estrogen level when estrogen secretion deficiency, the expression of estrogen receptor on genital system tissue cell can also be promoted simultaneously, estrogen increases glycogen generation in conjunction with estrogen receptor on vagina tissue, be conducive to Bacillus acidi lactici and lactic acid maintenance acid vagina environment is generated by degradation glycogen, it resists pathogenic bacteria and prevents senile vahinitis, it can increase vaginal lubrication degree simultaneously and wettability avoid vaginal dryness and atrophy, and prevent or improve female reproductive system retrogression pathological changes in a manner of safely and effectively.
Description
Technical field
The present invention relates to a kind of biomedicine field, more particularly to it is a kind of for the anti-ageing reparation product of female reproductive system and
Preparation method.
Background technique
The reproductive system organs of women include body of gland, ovary, uterus, uterine neck, vagina and vulva, the operation master of reproductive system
To be adjusted by the estrogen level of ovarian secretion, entire reproductive system physiological function peaked at 30 years old or so, then with
The increase estrogen level at age be gradually reduced, reproductive system function also starts that decline trend is presented, with reproductive system aging
For source, and then cause the aging of female body items function.
The symptom of female reproductive system aging is not only embodied on reproductive organs, such as vaginal atrophy, vagina epithelium mucous membrane
Thinning, reproductive system self-cleaning ability decline, is easy bacterial infection initiation inflammation, vaginal dryness relaxation, body of gland point at resistance decline
Ability decline, sexual function decline, sexual desire reduction etc. are secreted, is also embodied on the other positions or function of body, such as due to ovary
Deposition of the estrogen control calcium of secretion on bone, estrogen reduction lead to osteoporosis；Estrin drop causes face to go out
Existing chloasma, hair it is withered it is matt, posture fertilizer is superfluous, insomnia forgetfulness, irritated suspicious etc..
With the extension of female life expectancy, the life of a minimum of one third of overwhelming majority women is by reproductive system aging now
Influence, but due to reproductive system aging and bring retrogression pathological changes do not cause enough attention, the various discomforts of bring also
There are no targetedly treatment technology and products for symptom.Most common treatment means are using estrogen replacement therapy, directly
Complementing estrogen is connect there are significant drawback, estrogen increases the activity of induced cancer gene, cancer morbidity is caused to improve, such as
Cause breast cancer and carcinoma of endometrium.
Summary of the invention
The present invention is provided a kind of for the anti-ageing reparation product of female reproductive system and its system to solve above-mentioned deficiency
Preparation Method is selected the prevention female reproductive system aging of the compositions such as phytoestrogen and is alleviated caused by female reproductive system aging
Malaise symptoms.
Above-mentioned purpose of the invention is realized by technical solution below: one kind being used for the anti-ageing reparation of female reproductive system
Product, main component include coumestrol, vitamin E, curcuma zedoary, Sodium Hyaluronate and collagen.
Phytoestrogen is divided into 4 major class: from the isoflavones of soybean and its derivative, using linseed oil as representative
Lignanoid, Coumarins containing coumestrol and using resveratrol as the Stilbene class of representative.These phytoestrogens and estradiol
Molecular structure it is similar, contain phenol ring, can with estrogen receptor ining conjunction with, molecular weight also with estradiol approach, with estrogen
Receptor plays the effect of agonist or antagonist after combining.The biofermentation that lignanoid mainly passes through intestinal flora is converted into intestines two
Pure and mild enterolactone plays estrogenic effect, and the lignanoid not being metabolized can detect in urine, illustrates that lignanoid mainly leads to
It crosses enteron aisle to be absorbed in the form of aglycon, this oestrogen-like hormone needs to be prepared into the product of oral form.Most study in Stilbene class
It is resveratrol, resveratrol is present in grape, peanut and Cranberry, and resveratrol passes through β-grape in enteron aisle and liver
Uronic acid enzyme and sulfatase metabolism, the effect of resveratrol, which is mainly manifested in, resists cancer cell and offer anti-oxidation protection.?
Coumestrol and estradiol are closest on molecular structure and molecular weight in all phytoestrogens, as depicted in figs. 1 and 2.
Documents and materials data show that the affinity of coumestrol and estrogen receptor is more compared to other phytoestrogens
Height, using estradiol as object of reference, the affinity of Genistein (soybean isoflavone) and estrogen receptor ER α and ER β are distinguished
For 4% and 87%, the affinity of daidzein (soybean isoflavone) and estrogen receptor ER α and ER β be respectively 0.1% and
0.5%, the affinity of coumestrol and estrogen receptor ER α and ER β is respectively 20% and 140%, it can be seen that plant is female to be swashed
Element is higher with the compatibility of estrogen receptor ER β, and the affinity of coumestrol and estrogen receptor is significantly higher than other plants
Estrogen.Phytoestrogen generally only has weak estrogen action, and agonist or antagonism can be played in conjunction with estrogen receptor
The dual regulation of agent, the deficiency of function of compensating estrogen when internal estrogen concentrations are low, when estrogen concentrations are excessively high again
The effect of antagonist can be played.
Curcuma zedoary has the function of anti-bacteria and anti-virus, resists cancer and strengthen immunity, clinically suppository made of curcuma zedoary
For treating cervical carcinoma, lotion made of curcuma zedoary is used for various cancers for treating vaginitis, injection made of curcuma zedoary.At this
Curcuma zedoary plays the effect of prevention of inflammation and cervical carcinoma in product.
Vitamin E is also known as tocopherol, maintains the normal function of reproductive organs, enhances ovarian function, promotes the maturation of ovarian follicle,
Increase corpus luteum, significant antioxidation can inhibit the oxidation of progesterone in vivo, to increase the effect of progesterone.
Sodium Hyaluronate and collagen play good trophism in the product.
Further, its ingredient is respectively coumestrol 0.1-10%, vitamin E 0.1-5%, cowherb according to mass concentration
Art 1-10%, Sodium Hyaluronate 0.1-5%, collagen 0.1-10%, glycerol 5-10%, pentanediol 2-5%, hydroxy ethyl fiber
Plain 1-1.5%, lactic acid 0.1-1%, sodium lactate 0.2-2%, purifying water surplus.Lactic acid and sodium lactate make product as pH adjusting agent
It is maintained at a pH environment that is lower, being suitable for vagina tissue.
Further, its ingredient according to mass concentration be respectively coumestrol 1%, vitamin E 0.5%, curcuma zedoary 5%,
HA 0.1%, collagen 1%, glycerol 10%, pentanediol 5%, hydroxyethyl cellulose 1.5%, lactic acid 0.5%, sodium lactate
1%, water surplus is purified.
Further, its ingredient further includes foaming agent, GTCC, cetostearyl alcohol and emulsifier.
A kind of preparation method for the anti-ageing reparation product of female reproductive system, dissolves Sodium Hyaluronate with purified water；To
Hydrolyzed Collagen is added in sodium hyaluronate solution；Glycerol is added to be uniformly mixed；In addition fine with pentanediol dispersion ethoxy
Dimension element；Sodium Hyaluronate mixture solution is added in hydroxy ethyl fiber agent dispersion system, 60 DEG C of stirring in water bath thickenings；To body
It is that vitamin E, curcuma zedoary and coumestrol is added after viscosity improves, is uniformly mixed；System weight is supplied with purified water；With cream
Acid and sodium lactate regulation system pH to 3.8-4.5 both obtain finished product.This is gel products, is applied to reproductive system use.
Further, with after lactic acid and sodium lactate regulation system pH to 3.8-4.5 use high-temperature sterilization or addition preservative
It is stored.
It is a kind of for the anti-ageing preparation method for repairing product of female reproductive system, by oil-soluble ingredients in raw material and water-soluble
Property ingredient it is separately formulated, then the stirring and dissolving at 80 DEG C respectively, stablizes at 80 DEG C respectively to water phase and oily phase raw material, by water
It is mutually slowly added in oily phase, mixture solution stirs 5-10min at 80 DEG C, then carries out sufficiently cream to mixture solution
Change, solution stirs 15-20min at 40 DEG C after emulsification, and control bacterium pressurization is filling, both obtains finished product.This is froth pulp, froth pulp
It can more fully be contacted with tissue, maximumlly play efficacy effect.
The present invention is for the purpose of preventing and improve female reproductive system aging, to avoid directly using estrogen bring cancer
Disease hidden danger, a kind of safety is filtered out from isoflavones, lignanoid, cumarin and the other phytoestrogen of four type of Stilbene class to be had
The estrogen-like matters of effect, while cooperating the curcuma zedoary that there is oxidation resistant vitamin E, reparation uterine neck enhancing to be immunized and having moisturizing profit
The hyaluronic acid etc. of sliding effect, can improve intracorporal estrogen level when estrogen secretion deficiency, while can also promote system genitale
The expression for the estrogen receptor on histocyte of uniting, estrogen generates glycogen with estrogen receptor in conjunction with to increase on vagina tissue,
Be conducive to Bacillus acidi lactici and lactic acid maintenance acid vagina environment is generated by degradation glycogen, resists pathogenic bacteria and prevent senile vagina
Inflammation, while can increase vaginal lubrication degree and wettability avoids vaginal dryness and atrophy, and prevent in a manner of safely and effectively or
Improve female reproductive system retrogression pathological changes.
Detailed description of the invention
Fig. 1 is the molecular structure of coumestrol；
Fig. 2 is the molecular structure of beta estradiol.
Specific embodiment
The present invention is described in further detail below with reference to embodiment.
Embodiment 1
One kind is saturating with suitable purified water dissolution 1g for anti-ageing reparation product of female reproductive system and preparation method thereof, 1.
Bright matter acid sodium；2. 10g Hydrolyzed Collagen is added into sodium hyaluronate solution；3. adding 100g glycerol, it is uniformly mixed；4.
In addition disperse 15g hydroxyethyl cellulose with 50g pentanediol；5. Sodium Hyaluronate mixture solution is added to hydroxy ethyl fiber
In agent dispersion system, 60 DEG C of stirring in water bath thickenings；6. it is fragrant that 5g vitamin E, 50g curcuma zedoary and 10g is added after system viscosity raising
The female phenol of beans, is uniformly mixed, and can increase homogeneous operation according to the actual situation；7. extremely with lactic acid and sodium lactate regulation system pH
3.8-4.5；8. supplying system to 1kg with purified water；9. high-temperature sterilization or the preservative of suitable dose can be added, both 1kg is solidifying
Glue finished product.
The estrogen-like action of product is evaluated:
40 8 week old are taken not mate female KM mouse, adaptive feeding is tested after a week, and 40 mouse are random
It is divided into 4 groups, every group of 10: 1. castration groups cut off bilateral ovaries；2. test group cuts off bilateral ovaries castration, third after castration
Week starts anti-ageing reparation gel prepared by application implementation example 1, gos deep into vagina administration with tack steel needle, dosage: every daily
Mouse 0.05g, successive administration 8 weeks；3. blank group: cutting off bilateral ovaries castration, start in third week after castration using physiology salt
Water gos deep into vaginal injection with tack steel needle, injection volume: daily every mouse 0.05g, continuous injection 8 weeks；4. control group: only going
Except around ovary and the adipose tissue of ovary same size.Pass through the estradiol content and vagina in comparison separate groups of mice serum
The expression of ER α and ER β act in epithelial tissue to evaluate product.
After being administered 8 weeks, 4 groups of animals win eyeball and take blood, and blood is stood after twenty minutes at room temperature, 2000 revs/min from
The heart 10 minutes, serum is taken to survey estradiol content.Estradiol concentration is measured using enzyme linked immunological kit.Meanwhile it will be at 4 groups of mouse
Extremely, paraffin section is made after taking vagina tissue to be fixed with neutral formalin, takes streptavidin parent's biotin-peroxidase connection method
(S-P method) measures the expression of ER α and ER β, and every group takes 10 slices, and every slice takes 5 visuals field, same times magnification at random
It is measured under number (× 200) same luminous intensity.All parameters are usedIt indicates, analyzed with SPSS 13.0, P < 0.01 indicates difference
There is extremely significant property.
Estradiol content measurement result is as shown in table 1, and castration group and blank group estradiol content are very low, test group estradiol
Concentration is lower compared with control group, but obviously high compared with castration group and blank group, each group heteropolar significant (the P < of inequality compared with the control group
0.01).It is insufficient that data result illustrates that the present invention can supplement internal estrogen secretion to a certain degree.
Estrogen content in 1. separate groups of mice serum of table
| Group | Quantity (only) | E2 concentration (mIU/ml) |
| Castration group | 10 | 1.175±0.038** |
| Test group | 10 | 3.832±0.581** |
| Blank group | 10 | 1.183±0.026** |
| Control group | 10 | 6.256±0.328 |
*: difference is extremely significant compared with the control group, P < 0.01.
Vagina tissue immunohistochemical staining result (table 2) shows ER α and ER β equal positive expression in vagina tissue, goes
Gesture group and blank group ER α and ER β expression are obviously weak compared with control group, and difference has extremely significant property (P < 0.01), test group vagina epithelium
ER α and ER β expression quantity and control group are suitable, and test group and control group comparing difference illustrate the present invention without conspicuousness (P > 0.05)
It can promote the expression of vaginal epithelial cell ER α and ER β.
2. separate groups of mice vagina tissue ER α and ER β expression of table
| Group | ERα | ERβ |
| Castration group | 0.363±0.023** | 0.148±0.015** |
| Test group | 0.497±0.031 | 0.331±0.017 |
| Blank group | 0.392±0.012** | 0.133±0.003** |
| Control group | 0.502±0.016 | 0.338±0.012 |
*: difference is extremely significant compared with the control group, P < 0.01.
Embodiment 2
One kind being used for the anti-ageing reparation froth pulp of reproductive system and preparation method, and product composition includes that mass concentration is respectively
Coumestrol 0.1%, vitamin E 0.5%, curcuma zedoary 5%, HA 0.1%, collagen 1%, foaming agent, GTCC and 16
The greases such as eight alcohol and emulsifier.
By in raw material oil-soluble ingredients and water soluble ingredient it is separately formulated, the then stirring and dissolving at 80 DEG C respectively, to
Water phase and oily phase raw material are stablized at 80 DEG C respectively, water phase are slowly added in oily phase, mixture solution stirs at 80 DEG C
5-10min, then fully emulsified to mixture solution progress, solution stirs 15-20min at 40 DEG C after emulsification, as needed
Then the preservative that suitable dose is added pressurize to carry out sterile pressurized after filling or feed liquid high-temperature sterilization filling, both at
Product.
The ingredient of the technical program is chosen and the selection of weight ratio can be carried out according to the range described in claim
It freely matches, does not illustrate one by one herein.
The above description is only an embodiment of the present invention, is not intended to limit the scope of the invention, all to utilize this hair
Equivalent structure or equivalent flow shift made by bright specification and embodiment content, it is relevant to be applied directly or indirectly in other
Technical field is included within the scope of the present invention.
Claims (7)
1. one kind is used for the anti-ageing reparation product of female reproductive system, it is characterised in that: main component includes coumestrol, vitamin
E, curcuma zedoary, Sodium Hyaluronate and collagen.
2. according to claim 1 a kind of for the anti-ageing reparation product of female reproductive system, it is characterised in that: its ingredient
It is respectively coumestrol 0.1-10%, vitamin E 0.1-5%, curcuma zedoary 1-10%, Sodium Hyaluronate 0.1- according to mass concentration
5%, collagen 0.1-10%, glycerol 5-10%, pentanediol 2-5%, hydroxyethyl cellulose 1-1.5%, lactic acid 0.1-1%,
Sodium lactate 0.2-2%, purifying water surplus.
3. according to claim 2 a kind of for the anti-ageing reparation product of female reproductive system, it is characterised in that: its ingredient
It is respectively coumestrol 1%, vitamin E 0.5%, curcuma zedoary 5%, HA 0.1%, collagen 1%, glycerol according to mass concentration
10%, pentanediol 5%, hydroxyethyl cellulose 1.5%, lactic acid 0.5%, sodium lactate 1%, purifying water surplus.
4. according to claim 1 a kind of for the anti-ageing reparation product of female reproductive system, it is characterised in that: its ingredient
It further include foaming agent, GTCC, cetostearyl alcohol and emulsifier.
5. a kind of preparation method for the anti-ageing reparation product of female reproductive system according to claim 1 to 3,
It is characterized in that: dissolving Sodium Hyaluronate with purified water；Hydrolyzed Collagen is added into sodium hyaluronate solution；Add glycerol
It is uniformly mixed；In addition disperse hydroxyethyl cellulose with pentanediol；Sodium Hyaluronate mixture solution is added to hydroxy ethyl fiber
In agent dispersion system, 60 DEG C of stirring in water bath thickenings；Vitamin E, curcuma zedoary and coumestrol, stirring are added after system viscosity raising
It is uniformly mixed；System weight is supplied with purified water；With lactic acid and sodium lactate regulation system pH to 3.8-4.5, finished product is both obtained.
6. according to claim 5 a kind of for the anti-ageing preparation method for repairing product of female reproductive system, feature exists
In: it is stored after lactic acid and sodium lactate regulation system pH to 3.8-4.5 is added using high-temperature sterilization or addition preservative.
7. according to claim 1 or 4 a kind of for the anti-ageing preparation method for repairing product of female reproductive system, feature
Be: by raw material oil-soluble ingredients and water soluble ingredient it is separately formulated, the then stirring and dissolving at 80 DEG C respectively, to water phase
Stablize at 80 DEG C respectively with oily phase raw material, water phase is slowly added in oily phase, mixture solution stirs 5- at 80 DEG C
10min, then fully emulsified to mixture solution progress, solution stirs 15-20min at 40 DEG C after emulsification, and control bacterium pressurization fills
Dress both obtains finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811423700.6A CN109589404A (en) | 2018-11-27 | 2018-11-27 | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811423700.6A CN109589404A (en) | 2018-11-27 | 2018-11-27 | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109589404A true CN109589404A (en) | 2019-04-09 |
Family
ID=65959700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811423700.6A Pending CN109589404A (en) | 2018-11-27 | 2018-11-27 | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109589404A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110917132A (en) * | 2019-12-19 | 2020-03-27 | 浙江因诺泰医疗器械有限公司 | Vaginal squamous epithelium repair aqua and preparation method thereof |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1795925A (en) * | 2004-12-30 | 2006-07-05 | 中国人民武装警察部队医学院 | Medication composition of plant estrogens for treating colpitis |
| CN1857310A (en) * | 2006-03-27 | 2006-11-08 | 上海双健现代药物技术咨询有限公司 | Vaginal adhesion preparation containing nano silver and its preparing process |
| CN101797304A (en) * | 2010-03-23 | 2010-08-11 | 杨霞 | Gel for adjusting microecology in vaginas of women |
| CN103239676A (en) * | 2013-04-22 | 2013-08-14 | 马南行 | Topical pharmaceutical composition for preventing and treating bacterial vaginosis |
| CN104548071A (en) * | 2015-01-27 | 2015-04-29 | 太原锦波生物医药科技有限公司 | Recombinant human-derived collagen vagina gel for vaginal dryness and preparation method thereof |
| WO2015135470A1 (en) * | 2014-03-13 | 2015-09-17 | 曾忠铭 | Composition for vagina and use of the composition |
| CN105169374A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Recombinant human collagen gel and preparation method thereof |
| CN105473137A (en) * | 2013-05-06 | 2016-04-06 | 株式会社爱茉莉太平洋 | Composition for preventing or treating symptoms of menopause comprising soybean extract comprising coumestrol as an active ingredient |
| CN106215250A (en) * | 2016-08-26 | 2016-12-14 | 易金阳 | A kind of recombination human source I-type collagen gel stent for slack vagina and preparation method thereof |
| CN106580871A (en) * | 2017-02-16 | 2017-04-26 | 杭州元研细胞生物科技有限公司 | Vaginal gel and preparation method thereof |
| CN106691969A (en) * | 2017-01-11 | 2017-05-24 | 珠海聚焦先导生物研究院有限公司 | Female private gel containing traditional Chinese medicine composition |
| CN107184911A (en) * | 2017-06-19 | 2017-09-22 | 太原谷歌医药科技有限公司 | One kind is used to prevent cervical carcinoma and treatment papillomavirus（HPV）Infection and the product and preparation method of colpitis |
| WO2018064978A1 (en) * | 2016-10-09 | 2018-04-12 | 曾忠铭 | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use |
-
2018
- 2018-11-27 CN CN201811423700.6A patent/CN109589404A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1795925A (en) * | 2004-12-30 | 2006-07-05 | 中国人民武装警察部队医学院 | Medication composition of plant estrogens for treating colpitis |
| CN1857310A (en) * | 2006-03-27 | 2006-11-08 | 上海双健现代药物技术咨询有限公司 | Vaginal adhesion preparation containing nano silver and its preparing process |
| CN101797304A (en) * | 2010-03-23 | 2010-08-11 | 杨霞 | Gel for adjusting microecology in vaginas of women |
| CN103239676A (en) * | 2013-04-22 | 2013-08-14 | 马南行 | Topical pharmaceutical composition for preventing and treating bacterial vaginosis |
| CN105473137A (en) * | 2013-05-06 | 2016-04-06 | 株式会社爱茉莉太平洋 | Composition for preventing or treating symptoms of menopause comprising soybean extract comprising coumestrol as an active ingredient |
| WO2015135470A1 (en) * | 2014-03-13 | 2015-09-17 | 曾忠铭 | Composition for vagina and use of the composition |
| CN104548071A (en) * | 2015-01-27 | 2015-04-29 | 太原锦波生物医药科技有限公司 | Recombinant human-derived collagen vagina gel for vaginal dryness and preparation method thereof |
| CN105169374A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Recombinant human collagen gel and preparation method thereof |
| CN106215250A (en) * | 2016-08-26 | 2016-12-14 | 易金阳 | A kind of recombination human source I-type collagen gel stent for slack vagina and preparation method thereof |
| WO2018064978A1 (en) * | 2016-10-09 | 2018-04-12 | 曾忠铭 | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use |
| CN106691969A (en) * | 2017-01-11 | 2017-05-24 | 珠海聚焦先导生物研究院有限公司 | Female private gel containing traditional Chinese medicine composition |
| CN106580871A (en) * | 2017-02-16 | 2017-04-26 | 杭州元研细胞生物科技有限公司 | Vaginal gel and preparation method thereof |
| CN107184911A (en) * | 2017-06-19 | 2017-09-22 | 太原谷歌医药科技有限公司 | One kind is used to prevent cervical carcinoma and treatment papillomavirus（HPV）Infection and the product and preparation method of colpitis |
Non-Patent Citations (4)
| Title |
|---|
| B M MARKAVERICH等: "Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats", 《ENVIRON HEALTH PERSPECT》 * |
| NITU DEBNATH等: "Uterotrophic responses and modulation of uterine gene expression induced by combinations of genistein and coumestrol in ovariectomized mice", 《THE BIOSCAN》 * |
| PATRICIA LWHITTEN等: "Neurobehavioral actions of coumestrol and related isoflavonoids in rodents", 《NEUROTOXICOLOGY AND TERATOLOGY》 * |
| 陈晓钢等: "香豆雌酚对去卵巢大鼠骨代谢生化指标的影响", 《中国骨质疏松杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110917132A (en) * | 2019-12-19 | 2020-03-27 | 浙江因诺泰医疗器械有限公司 | Vaginal squamous epithelium repair aqua and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weaver et al. | Soy isoflavones and bone health: the relationship is still unclear | |
| AU2009200258B2 (en) | Methods of treating and/or suppressing weight gain | |
| Albertazzi et al. | The effect of dietary soy supplementation on hot flushes | |
| Vincent et al. | Soy isoflavones: are they useful in menopause? | |
| Wagner et al. | Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys | |
| Anderson et al. | Health potential of soy isoflavones for menopausal women | |
| Cassidy | Potential risks and benefits of phytoestrogen-rich diets | |
| Clarkson et al. | The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy | |
| Umland et al. | Phytoestrogens as therapeutic alternatives to traditional hormone replacement in postmenopausal women | |
| Clarkson et al. | 4Phytoestrogens and coronary heart disease | |
| Urasopon et al. | Pueraria mirifica, a phytoestrogen-rich herb, prevents bone loss in orchidectomized rats | |
| ZA200005070B (en) | Therapy of estrogen-associated disorders. | |
| US20060193929A1 (en) | Method for treating or preventing symptoms associated with menopause | |
| CN101443017A (en) | Medication against breast cancer and related diseases | |
| CA2504682A1 (en) | Use of equol for treating androgen mediated diseases | |
| US5708038A (en) | Method of using aloe vera as a biological vehicle | |
| Arjmandi et al. | The ovarian hormone deficiency-induced hypercholesterolemia is reversed by soy protein and the synthetic isoflavone, ipriflavone | |
| GUO et al. | The effect of administration of rutin on plasma levels of estrogen, prolactin, growth hormone and gene expression of their receptors in mammary glands in ovariectomized rats | |
| Muangman et al. | Clinical Trial of the Phytoestrogen-rich Herb; Pueraria mirifica as a Crude Drug in the Treatment of Symptoms in Menopausal Women | |
| CN108785163A (en) | Chest enlarge emulsifiable paste and preparation method thereof and application method | |
| CN109589404A (en) | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof | |
| Chalkidou et al. | The Comparative Study of the Administration of the Combination Preparation of Isoflavones and Hyaluronic Acid in Menopausal Women for the Treatment of the Symptoms of Menopause, Urogenital Atrophy and Oteoporosis in Relation to Existing Hormone Replacement Therapies | |
| WO2008004223A2 (en) | Compounds and methods for the treatment of menopause and bone related disorders | |
| Murray | Natural progesterone: what role in women’s health care | |
| WO2022264127A1 (en) | Compositions for treatment of vaginal atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190426 Address after: 310000 Yuhang District, Hangzhou City, Zhejiang Province, No. 2959 Yuhangtang Road, Cangqian Street, 4 buildings and 1 storey Applicant after: Zhejiang Inotai Medical Devices Co.,Ltd. Address before: 310000 Room 458, Building 3, No. 1, Luting Road, Cangqian Street, Yuhang District, Hangzhou City, Zhejiang Province Applicant before: HANGZHOU YUANYAN CELL BIOTECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190409 |
|
| RJ01 | Rejection of invention patent application after publication |